The Efficacy of Imipramine in Treatment of Refractory Functional Dyspepsia
The Efficacy of Imipramine in Treatment of Functional Dyspepsia: A Double Blind Randomized Placebo Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Hong Kong, Hong Kong
- Prince of Wales Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients fulfill the diagnostic criteria of functional dyspepsia as defined by Rome II criteria
- Age > 18 years old
- Failure of treatment response to PPI, H2 receptor antagonist fo 8 weeks and domperidone for 4 weeks
Exclusion Criteria:
- Organic pathology detected by endoscopy
- GERD or IBS as dominant compliant
- Presence of any alarm symptom: anemia, recurrent vomiting, weight loss
- Concomitant Helicobacter pylori infection
- Concomitant use of neuroleptic or antidepressant, NSAID
- Previous gastrointestinal surgery
- Cardiac arrhythmia, untreated glaucoma or benign prostate hypertrophy
- Pregnancy
- Known hypersensitivity or contraindication for tricyclic antidepressant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Imipramine
Imipramine 25mg nocte for first 2 weeks then Imipramine 50 mg nocte for 10 weeks
|
25mg nocte for first 2 weeks then 50 mg nocte for 10 weeks
|
|
Placebo Comparator: Placebo
Placebo 1 tablet for first 2 weeks then Placebo 2 tablets for 10 weeks
|
One tab nocte for first 2 weeks then 2 tabs for 10 weeks
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall satisfactory relief (Global Symptom Assessment) at 12 weeks
Time Frame: 12 weeks
|
It is defined as a response of "Yes" to the question: "Do you experience overall satisfactory relief of dyspeptic symptom with the current treatment?"
by global symptom assessment.
|
12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Individual dyspeptic symptom scores
Time Frame: 12 weeks
|
8-item dyspepsia symptom score questionnaire assessing epigastric pain, epigastric burning, postprandial fullness, early satiety, belching, bloating, nausea, and vomiting on a scale of 0-3 over the last 7 days
|
12 weeks
|
|
Days of sleep disturbance
Time Frame: 12 weeks
|
Effect on sleep will be assessed by asking patients if they had insomnia on ≥1 day per week
|
12 weeks
|
|
Mood assessment
Time Frame: 12 weeks
|
Effect on mood will be assessed using the hospital anxiety and depression scale (HADS)
|
12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Signs and Symptoms, Digestive
- Dyspepsia
- Gastrointestinal Diseases
- Digestive System Diseases
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Antidepressive Agents
- Antidepressive Agents, Tricyclic
- Adrenergic Uptake Inhibitors
- Imipramine
Other Study ID Numbers
Other Study ID Numbers
- DA Study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.